Ezetimibe PCD Pharma Franchise Company
Cafoli Lifecare is a WHO-GMP certified pharmaceutical company offering 10 Ezetimibe formulations for PCD pharma franchise, distributors and monopoly marketing partners across India. The range covers standalone tablets and fixed-dose statin combinations.
What is Ezetimibe?
Ezetimibe is a cholesterol-absorption inhibitor that reduces the amount of cholesterol absorbed from the intestine, lowering LDL (“bad”) cholesterol. It is used alone or, more often, added to a statin for patients who need further LDL reduction. Reference: PubChem.
Available Ezetimibe Formulations
Cafoli Lifecare's Ezetimibe portfolio is available as Tablet, including single-molecule strengths and combinations with rosuvastatin and atorvastatin.
Therapeutic Applications
Ezetimibe is used for primary hypercholesterolaemia and mixed dyslipidaemia, usually in combination with a statin for additional LDL lowering. It is prescribed by cardiologists, general physicians, diabetologists and endocrinologists as part of long-term lipid management.
Why Ezetimibe is a High-Potential Molecule for Distributors
Dyslipidaemia management is a large, chronic-therapy segment, and statin + ezetimibe combinations are increasingly first-line for patients not at LDL goal on a statin alone. This growing, lifelong-therapy demand makes Ezetimibe a strong, high-retention addition to a cardiac-diabetic franchise range.
Why Choose Cafoli Lifecare
Cafoli Lifecare offers monopoly (district-wise) distribution rights, WHO-GMP and DCGI-approved manufacturing, attractive net rates, complete promotional inputs (visual aids, MR bags, product cards) and prompt dispatch — trusted by 1000+ franchise partners across India.
References
- PubChem – Ezetimibe
- PubMed – Ezetimibe literature
Our formulations of Ezetimibe find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: